Penserra Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Penserra Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-17,908	Closed	-$330K	–	1457
2021 Q4	$330K	Buy	17,908 +3,412	+24%	+$92.4K	0.01%	578
2021 Q3	$443K	Buy	14,496 +2,331	+19%	+$91.9K	0.01%	528
2021 Q2	$667K	Buy	12,165 +8,165	+204%	+$453K	0.01%	447
2021 Q1	$236K	Buy	4,000 +520	+15%	+$34.2K	﹤0.01%	554
2020 Q4	$130K	Buy	3,480 +326	+10%	+$12.2K	﹤0.01%	583
2020 Q3	$170K	Sell	3,154 -779	-20%	-$141K	0.01%	454
2020 Q2	$989K	Sell	3,933 -1,018	-21%	-$206K	0.05%	275
2020 Q1	$978K	Buy	+4,951	New	+$837K	0.07%	267

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Penserra Capital Management's CRBP Position: Q1 2022 in Review

Penserra Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2022, closing a stake of 17,908 shares — an estimated $330K sold.

Penserra Capital Management first reported a position in CRBP in Q1 2020 and held it in 8 quarters. The position peaked at $989K in Q2 2020. 72 funds tracked by Wall St. Rank hold CRBP as of Q1 2022.

Penserra Capital Management reported no remaining Corbus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Penserra Capital Management sold 17,908 Corbus Pharmaceuticals shares in Q1 2022, an estimated $330K.
Penserra Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Penserra Capital Management's Corbus Pharmaceuticals position peaked at $989K in Q2 2020.
72 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2022.

Based on Penserra Capital Management's 13F filing for Q1 2022, filed 13 May 2022.